Flexible-Dose Trial in Early Parkinson's Disease (PD)

Summary

The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

Timeline

Start

2020-01-06

Primary completion

2024-10-01

Completion

2024-10-01

Publications

• Fernandez HH, Bhatia P, Cloud L, Fietzek UM, Matarazzo M, Molho E, Peckham E, Tarakad A, Combs C, Leoni M, Chang I, Tringali S, Boiser J, Sanchez R, Zadikoff C. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026 Aug;25(8):721-730. doi: 10.1016/S1474-4422(26)00215-2.

Drugs

Indications